K052079 1.62

OCT 2 1 2005

a Johnson-Johnson company

## DePuy Orthopaedics, Inc.

PO Box 988 700 Orthopaedic Drive Warsaw, Indiana 46581-0988 USA

Tel: +1 (574) 267 8143

**510(k) SUMMARY** 

Submitted July 28, 2005

NAME OF FIRM:

DePuy Orthopaedics, Inc. 700 Orthopaedic Drive Warsaw, IN 46580

510(K) CONTACT:

Keli K. Hankee

Clinical Research Associate DePuy Orthopaedics, Inc.

PO Box 988

700 Orthopaedic Drive Warsaw, IN 46580

TRADE NAME:

DePuy Pinnacle\* Constrained Acetabular Liners

COMMON NAME:

Acetabular Cup Liner

**CLASSIFICATION:** 

Class II, per 21 CFR, 888.3310

Hip joint metal/polymer/ metal, constrained, cemented or

uncemented prosthesis

**DEVICE PRODUCT CODE:** 

87 KWZ

SUBSTANTIALLY

**EQUIVALENT DEVICES:** 

Osteonics Constrained Acetabular Inserts DePuy Pinnacle<sup>®</sup> Constrained Acetabular Liners K152079 2012

### **DEVICE DESCRIPTION:**

The Pinnacle\* Constrained Acetabular Liner is part of a modular system designed to replace the natural articular surface of the hip joint in total hip replacement. The liner is manufactured from ultra high molecular weight polyethylene (UHMWPE), which locks into a porous coated, hemispherical outer shell component manufactured from titanium alloy (Ti-6Al-4V). The liner component articulates with a metal femoral head of an appropriate diameter.

The Pinnacle\*\* Constrained Acetabular Liner mechanically constrains the femoral head within the ID of the liner by providing greater than 180 degrees femoral head capture combined with a titanium constraining ring which fits over the opening diameter of the liner. The UHMWPE liner is held in the metal shell by means of a titanium locking ring.

The subject Pinnacle® Constrained Acetabular Liners are UHMWPE acetabular cup liners that are available in a lateralized neutral or lateralized face-changing orientation. The liners have inner diameters (ID) intended for use with Self-Centering (bipolar) femoral heads within the 40mm-44mm size range. The 62mm-76mm outer diameters (ODs) are geometrically the same as other smaller OD Pinnacle Acetabular Liners cleared in K043058.

#### INDICATIONS AND INTENDED USE:

#### Indications:

The Pinnacle\* Constrained Acetabular Liner is indicated for use as a component of a total hip prosthesis in primary or revision patients at high risk of hip dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease or intraoperative instability.

The Pinnacle\* Constrained Acetabular Liner is indicated for use with the Pinnacle\* Acetabular Cup in cementless application.

#### **Intended Use:**

The subject Pinnacle\* Constrained Acetabular Liner is intended to be used with the DePuy Pinnacle\* metal acetabular shells and Self-centering<sup>TM</sup> (bipolar) heads to resurface the acetabular socket in cementless total hip arthroplasty.

#### **Basis of Substantial Equivalence:**

The DePuy Pinnacle\* Constrained Acetabular Liner (lateralized neutral and lateralized face-changing), described in this submission is substantially equivalent to the predicate devices based on similarities in design, intended use, material and manufacturing methods. The design is identical to the DePuy predicate and does not raise any new issues of safety or effectiveness.

DePuy believes that the DePuy Pinnacle \* Constrained Acetabular Liner is substantially equivalent to the previously cleared and approved devices.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## OCT 2 1 2005

Keli K. Hankee Clinical Research Associate DePuy Orthopaedics, Inc PO Box 988 700 Orthopaedic Drive Warsaw, Indiana 46581

Re: K052079

Trade/Device Name: Pinnacle® Constrained Acetabular Liner

Regulation Number: 21 CFR 888.3310

Regulation Name: Hip joint metal/polymer constrained

cemented or uncemented prosthesis

Regulatory Class: II Product Code: KWZ Dated: July 29, 2005

Received: August 02, 2005

## Dear Ms. Hankee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0210. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>.

Sincerely yours,

 $\mathcal{C}_{\mathbf{A}}$ 

Mark N. Melkerson Acting Director

Division of General, Restorative, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

K052079

# **Indications for Use**

510(k) Number (if known):
Indications for Use:
The Pinnacle <sup>®</sup> Constrained Acetabular Liner is indicated for use as a component of a total hip prosthesis in primary or revision patients at high risk of hip dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease or intraoperative instability.
The Pinnacle* Constrained Acetabular Liner is indicated for use with the Pinnacle* Acetabular Cup in cementless application.
Prescription UseX AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)  (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH. Office of Device Evaluation (ODE)
Page of
(Posted November 13, 2003)
(Division Sign-Off)
Division of General, Restorative, and Neurological Devices
510(k) Number K052079